Group 1 - The core point of the news is that Tongyuan Kang Pharmaceutical-B (02410) has announced a placement agreement to issue 9.23 million shares at a price of HKD 17.01 per share, which represents a discount of approximately 19% compared to the last closing price of HKD 21.0 on July 28, 2025 [1][2] - The placement will result in an increase of approximately 2.46% in the total issued H-shares and about 2.43% in the total issued shares of the company [1] - The expected total proceeds from the placement are approximately HKD 157 million, with a net amount of about HKD 155 million after deducting commissions and related costs [2] Group 2 - The company plans to allocate approximately 60% of the net proceeds from the placement for research and commercialization of its existing pipeline [2] - About 30% of the net proceeds will be used to enhance internal research capabilities and expand the product portfolio [2] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [2]
港股异动 | 同源康医药-B(02410)涨超3% 拟折让19%配股净筹约1.55亿港元 用于现有管线研发及商业化等